AGR3

Across TCGA pan-cancer cohorts, AGR3 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated AGR3 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher AGR3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated AGR3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and COAD show a favorable association.

PDAC, COAD, and LUAD are the cancer types where AGR3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	II,III,IV	0.765	0.429	<.001	36	view →
COAD	DFS	Median	All	1.000	0.886	.020	12	view →
LUAD	DFS	Quartile	All	0.806	0.996	.017	11	view →
CCRCC	DFS	Quartile	All	0.858	0.431	.006	9	view →
UCEC	OS	Median	II,III,IV	0.628	1.000	.013	8	view →
HNSC	DFS	Median	III,IV	0.489	0.718	.009	7	view →
LSCC	DFS	Tertile	All	0.881	1.000	.007	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

AGR3–PDAC (OS)

Open the PDAC breakdown →